Sparstolonin B
Based on 10 publication(s) in Google Scholar
Sparstolonin B acts as a selective TLR2 and TLR4 antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-HIV and anticancer activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.77%
- No. CAS: 1259330-61-4
- Fòrmula: C15H8O5
- Peso molecular:268.22
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-11109
ResatorvidTLR4 Inhibitor -
HY-100461
C29TLR2 Inhibitor -
HY-139397
TJ-M2010-5MyD88 Inhibitor -
HY-123942
DiprovocimTLR1/TLR2 Agonist -
HY-112146
MMG-11TLR2 Antagonist -
HY-P10586A
Macrophage-activating lipopeptide 2 TFATLR Agonist -
HY-135042
CAY10614TLR4 Antagonist -
HY-122482
β-RubromycinHIV Reverse Transcriptase Inhibitor -
HY-119789
AlbofunginAntibiotic, Antitumor -
HY-13502S
Mitoxantrone-d8Stable Isotope -
HY-103697A
Gardiquimod diTFATLR7/8 Agonist -
HY-103697AR
Gardiquimod diTFA (Standard)TLR7/8 Agonist
Publications Citing Use of MedChemExpress (MCE) Sparstolonin B
More- J Nanobiotechnology. 2024 Dec 18;22(1):759. [Abstract]
- J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
- Cell Commun Signal. 2025 Aug 26;23(1):381. [Abstract]
- Phytomedicine. 2025 Dec:149:157578. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Int J Pharm X. 2026 Feb 24:11:100510. [Abstract]
- J Clin Transl Hepatol. 2026 Apr 28;14(4):440-451.
- Biofactors. 2021 Sep;47(5):865-878. [Abstract]
- Exp Cell Res. 2022 May 18;417(1):113214. [Abstract]
- World J Surg Oncol. 2022 Aug 25;20(1):266. [Abstract]
Customer Validation & Images
-
Others
-
Others
-
Others
-
Flow Cytometry
-
RT-PCR
Actividad biológica
Descripciòn
|
TLR2 |
TLR4 |
HIV-1 |
In Vitro
Sparstolonin B (1-20 μM; 2-4 days) inhibits cell growth and viability of neuroblastoma cells[3].
Sparstolonin B inhibits TLR ligand-induced cytokine expression in mouse macrophages. Sparstolonin B inhibits MyD88 recruitment to TLR4 and TLR2[1].
Sparstolonin B generates reactive oxygen species (ROS) in neuroblastoma cells. Sparstolonin B reduces expression of N-myc in neuroblastoma cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y, IMR-32, NGP, SKNF-1 and SK-N-BE(2) cells
-
Concentration:1 µM, 5 µM, 10 µM or 20 µM
-
Incubation Time:2-4 days
-
Result:Effectively and dose-dependently inhibits the viability of all neuroblastoma cell lines after 2 days (SH-SY5Y and IMR-32), 3 days (NGP cells) or 4 days (SKNF-1 and SK-N-BE(2) cells) treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-6-week-old male C57Bl/6 mice (body weight 18-20 g)[1]
-
Dosage:100 μg/mouse
-
Administration:I.p.
-
Result:Significantly lower TNFα and IL-1β expression levels in LPS-induced sepsis mouse model.
Chemical Information
-
No. CAS 1259330-61-4
-
Appearance Solid
-
Peso molecular 268.22
-
Fòrmula C15H8O5
-
Color Light yellow to yellow
-
SMILES
O=C1OC=C2C3=C(OC4=C2C1=C(O)C=C4)C=CC(O)=C3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
Sparstolonin B potentiates the antitumor activity of nanovesicle-loaded drugs by suppressing the phagocytosis of macrophages in vivo. [Abstract]2024 Dec 18;22(1):759. PMID: 39696573 -
J Exp Clin Cancer Res
Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1-IL-1β axis. [Abstract]2025 Sep 30;44(1):277. PMID: 41029721
Sparstolonin B purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
Rescue experiments assessing the effect of adding recombinant SAA1 protein (HY-P70510; 200 ng/ml; ; 20–24 h) or the TLR2/4 inhibitor SsnB (Sparstolonin B; HY-116213; 20 µM; 20–24 h) on the ability of A2780 cell supernatants to recruit MDSCs.
Sparstolonin B purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
Rescue experiments assessing the effect of adding recombinant SAA1 protein (HY-P70510; 200 ng/ml; ; 20–24 h) or the TLR2/4 inhibitor SsnB (Sparstolonin B; HY-116213; 20 µM; 20–24 h) on the ability of A2780 cell supernatants to recruit MDSCs.
Sparstolonin B purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
Rescue experiments assessing the effect of recombinant SAA1 protein (HY-P700309; 200 ng/ml; ; 20–24 h) or SsnB (Sparstolonin B; HY-116213; 20 µM; 20–24 h) on the ability of ID8 cell supernatants to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Tukey’s multiple comparisons test.
Sparstolonin B purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
Rescue experiments assessing the effect of adding recombinant SAA1 protein (HY-P70510; 200 ng/ml; ; 20–24 h) or the TLR2/4 inhibitor SsnB (Sparstolonin B; HY-116213; 20 µM; 20–24 h) on the ability of A2780 cell supernatants to induce GMP differentiation into MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Tukey’s multiple comparisons test.
Sparstolonin B purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. [Abstract]
IL-1β expression and secretion in MDSCs after adding the TLR2/4 inhibitor SsnB (Sparstolonin B; HY-116213; 20 µM; 20–24 h) to SAA1 (HY-P70510; 200 ng/ml; ; 20–24 h) treatment, detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test.
-
Cell Commun Signal
2025 Aug 26;23(1):381. PMID: 40859363
Sparstolonin B purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Aug 26;23(1):381. [Abstract]
Neutrophils were pretreated with the TLR2 and TLR4 inhibitor Sparstolonin B (SsnB) (HY-116213; 10 µM), the TLR2 inhibitor C29 (HY-100461; 100 µM), or the TLR4 inhibitor C34 (TLR4-IN-C34; HY-107575; 10 µM) for 30 min before stimulation with calreticulin. Transwell migration assay. The lower chambers were loaded with blank culture medium (a), calreticulin (b), calreticulin with SsnB (c), calreticulin with C29 (d), or calreticulin with C34 (e). CFSE-labeled neutrophils were loaded into the upper chamber and allowed to migrate for 3 h.
Sparstolonin B purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Aug 26;23(1):381. [Abstract]
Neutrophils were pretreated with the TLR2 and TLR4 inhibitor Sparstolonin B (SsnB) (HY-116213; 10 µM), the TLR2 inhibitor C29 (HY-100461; 100 µM), or the TLR4 inhibitor C34 (TLR4-IN-C34; HY-107575; 10 µM) for 30 min before stimulation with calreticulin. F-actin was detected for 30 min the incubation of neutrophils with calreticulin in the presence of the respective inhibitors (scale bars = 10 μm).
Sparstolonin B purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Aug 26;23(1):381. [Abstract]
Neutrophils were incubated in calreticulin with or without inhibitors of TLR2/TLR4 (SsnB; HY-116213; 10 µM), TLR2 (C29; HY-100461; 100 µM), or TLR4 (C34; TLR4-IN-C34; HY-107575; 10 µM) for 0 min, 1 min, 3 min, or 5 min. The cell lysate was prepared and subjected to western blotting for analysis of the expression of Cdc42, Rac1, and RhoA. Densitometric analysis of each protein band is shown below the blots, representing grayscale quantification relative to internal controls
-
Phytomedicine
Sparstolonin B and Curcumin alleviate atherogenesis by modulating T helper 17-stromal cell interactions associated with interleukin-17 receptor A (IL-17RA) - transforming growth factor-β-activated kinase 1 (TAK1) - nuclear factor-kappa B (NF-κB) signaling. [Abstract]2025 Dec:149:157578. PMID: 41308385 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Int J Pharm X
GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma. [Abstract]2026 Feb 24:11:100510. PMID: 41783645 -
-
Biofactors
CDCA7-regulated inflammatory mechanism through TLR4/NF-κB signaling pathway in stomach adenocarcinoma. [Abstract]2021 Sep;47(5):865-878. PMID: 34339079 -
Exp Cell Res
2022 May 18;417(1):113214. PMID: 35594953 -
World J Surg Oncol
Achaete-scute complex-like 2 regulated inflammatory mechanism through Toll-like receptor 4 activating in stomach adenocarcinoma. [Abstract]2022 Aug 25;20(1):266. PMID: 36008864
Solvente y solubilidad
In Vitro:
DMSO : 10 mg/mL (37.28 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (18.64 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Liang Q, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286(30):26470-26479. [Content Brief]
[2]. Deng X, et al. The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription. Virol J. 2015;12:108. Published 2015 Jul 25. [Content Brief]
[3]. Kumar A, et al. Sparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cells [published correction appears in PLoS One. 2016;11(7):e0159082]. PLoS One. 2014;9(5):e96343. Published 2014 May 1. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7283 mL | 18.6414 mL | 37.2828 mL | 93.2071 mL |
| 5 mM | 0.7457 mL | 3.7283 mL | 7.4566 mL | 18.6414 mL | |
| 10 mM | 0.3728 mL | 1.8641 mL | 3.7283 mL | 9.3207 mL | |
| 15 mM | 0.2486 mL | 1.2428 mL | 2.4855 mL | 6.2138 mL | |
| 20 mM | 0.1864 mL | 0.9321 mL | 1.8641 mL | 4.6604 mL | |
| 25 mM | 0.1491 mL | 0.7457 mL | 1.4913 mL | 3.7283 mL | |
| 30 mM | 0.1243 mL | 0.6214 mL | 1.2428 mL | 3.1069 mL |
Sparstolonin B Related Classifications
HY-116213 Related Classifications
Powered by Bioz